Advertisement

Organisation › Details
Nabriva (Group)
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics believes lefamulin is well-positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. Nabriva Therapeutics is exploring potential further development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use. Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the U.S., Europe and Japan. *
![]() |
Start | 2006-01-01 splitoff |
Today | Nabriva Therapeutics AG | |
Predecessor | Antibiotic Research Institute (ABRI) (Sandoz) | |
![]() |
Industry | anti-infective drug |
![]() |
Person | Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan) |
![]() |
Region | Wien (Vienna) |
Country | Austria | |
Street | 20 Leberstr. | |
City | 1110 Wien | |
Tel | +43-1-74093-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2019-01-31) |
Currency | USD | |
Annual sales | 9,656,000 (revenues, total, consolidated (2018) 2018-12-31) | |
Profit | -114,780,000 (2018-12-31) | |
Cash | 102,003,000 (2018-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Nabriva (Group)
- [1] Nabriva Therapeutics plc. (2/26/21). "Press Release: Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer". Dublin & King of Prussia, PA....
- [2] Nabriva Therapeutics plc. (12/20/19). "Press Release: Nabriva Therapeutics Announces $20 Million Registered Direct Offering". Dublin & King of Prussia, PA....
- [3] Nabriva Therapeutics plc. (12/20/19). "Press Release: Nabriva Therapeutics Resubmits New Drug Application for Intravenous Contepo (fosfomycin) for Injection". Dublin....
- [4] Nabriva Therapeutics plc. (8/19/19). "Press Release: Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP)". Dublin....
- [5] Nabriva Therapeutics plc. (8/16/19). "Press Release: Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous Contepo (fosfomycin) for Injection". Dublin....
- [6] Nabriva Therapeutics plc. (2/19/19). "Press Release: Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults". Dublin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top